A Named Patient Program (NPP), a compassionate use program of ABO 101
Latest Information Update: 04 Aug 2021
Price :
$35 *
At a glance
- Drugs ABO-101 (Primary)
- Indications Mucopolysaccharidosis III
- Focus Expanded access; Therapeutic Use
- Sponsors Abeona therapeutics
- 04 Aug 2021 New trial record
- 28 Jul 2021 According to an Abeona therapeutics media release, to date, three patients have been treated and a fourth patient will be treated with the higher dose through this program. The company intends to pool data from the all patients from "Transpher B" study and this "Named Patient Program " to assess therapeutic effect.